Search

Displaying results 491 - 500 of 4339 in total
  1. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older.[L47092,L47127] It was further approved by the EMA in September 2023.

  2. Drug

    Carbinoxamine

    go.drugbank.com/drugs/DB00748
    Approved

    This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. … The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many

  3. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. … [L44642] It also received approval for preventive treatment of adult migraine by the EMA in August 2023.

  4. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    [L15017, L15022] Comirnaty received fast track designation by the U.S. FDA on July 13, 2020. … Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350]

  5. Drug

    Vaborbactam

    go.drugbank.com/drugs/DB12107
    ApprovedInvestigational

    Vaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).

  6. Drug

    Neomycin

    go.drugbank.com/drugs/DB00994
    ApprovedInvestigationalVet approved

    [A175042] Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is … also used in combination with [polymyxin B] sulfates and [hydrocortisone] in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by

    Mixtures: Bus and Classroom Yellow, Care Bus and Classroom Yellow
  7. Drug

    Losartan

    go.drugbank.com/drugs/DB00678
    ApprovedInvestigational

    [L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.

    Mixtures: LOSAMLO 50MG/10MG FTA, LOSAMLO 50MG/10MG FTAProducts: LOSAR DENK 50MG, LOSARTAN 50MG
  8. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito. … It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118

  9. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    and pediatric patients aged 2 years and older. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults

  10. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    [L23524] In November 2021, the same indication was approved by the EMA. … Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA.